Immuneering to Present at the ESMO Congress 2026

Trial in progress poster will highlight the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer patients -NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation NASDAQ:IMRX, a late-stage clinical oncology company focused on keeping cancer patie…